来自合理筛选供体的粪菌移植改善肝性脑病:一项随机临床试验
在反复发作肝性脑病的肝硬化门诊男性患者中开展的开放标签随机试验显示,与仅标准治疗相比,接受抗生素预处理后单次粪菌移植灌肠的患者严重不良事件更少、认知改善、菌群失调改善,且肝性脑病再发更少。
要点
- 粪菌移植组严重不良事件2例(20%),标准治疗组8例(80%)共11次严重不良事件(P = 0.02)。
- 标准治疗组5例、粪菌移植组0例出现进一步肝性脑病(P = 0.03)。
- 认知仅在粪菌移植组改善,标准治疗组菌群与MELD评分 throughout 保持相似。
核心结论
- 来自合理筛选供体的粪菌移植减少了反复发作肝性脑病肝硬化患者的住院、改善了认知和菌群失调。
研究设计与样本
- 开放标签随机临床试验,5个月随访,纳入接受标准治疗的反复发作肝性脑病肝硬化门诊男性患者,1:1随机分组。
主要发现
- 粪菌移植组8例中2例(20%)出现严重不良事件,标准治疗组8例中8例(80%)共11次严重不良事件,两例均与粪菌移植无关(P = 0.02)。
- 标准治疗组5例、粪菌移植组0例出现进一步肝性脑病(P = 0.03)。
- 认知在粪菌移植组改善,标准治疗组未改善。
- 抗生素后MELD评分短暂恶化,粪菌移植后恢复至基线。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Recurrent hepatic encephalopathy (HE) is a leading cause of readmission despite standard of care (SOC) associated with microbial dysbiosis. Fecal microbiota transplantation (FMT) may improve dysbiosis; however, it has not been studied in HE. We aimed to define whether FMT using a rationally derived stool donor is safe in recurrent HE compared to SOC alone. An open-label, randomized clinical trial with a 5-month follow-up in outpatient men with cirrhosis with recurrent HE on SOC was conducted with 1:1 randomization. FMT-randomized patients received 5 days of broad-spectrum antibiotic pretreatment, then a single FMT enema from the same donor with the optimal microbiota deficient in HE. Follow-up occurred on days 5, 6, 12, 35, and 150 postrandomization. The primary outcome was safety of FMT compared to SOC using FMT-related serious adverse events (SAEs). Secondary outcomes were adverse events, cognition, microbiota, and metabolomic changes. Participants in both arms were similar on all baseline criteria and were followed until study end. FMT with antibiotic pretreatment was well tolerated. Eight (80%) SOC participants had a total of 11 SAEs compared to 2 (20%) FMT participants with SAEs (both FMT unrelated; P = 0.02). Five SOC and no FMT participants developed further HE (P = 0.03). Cognition improved in the FMT, but not the SOC, group. Model for End-Stage Liver Disease (MELD) score transiently worsened postantibiotics, but reverted to baseline post-FMT. Postantibiotics, beneficial taxa, and microbial diversity reduction occurred with Proteobacteria expansion. However, FMT increased diversity and beneficial taxa. SOC microbiota and MELD score remained similar throughout. CONCLUSION: FMT from a rationally selected donor reduced hospitalizations, improved cognition, and dysbiosis in cirrhosis with recurrent HE. (Hepatology 2017;66:1727-1738).
引用
- Bajaj JS, Kassam Z, Fagan A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology. 2017. PMID: 28586116. doi:10.1002/hep.29306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。